EUVIMEDEUVIMED entdecken
Crossref

Bone loss after discontinuation of denosumab: the devil is in the details

Salvatore Minisola, Cristiana Cipriani iD, Luciano Colangelo, Jessica Pepe iD

Journal of Bone and Mineral Research · 2024

DOI: 10.1093/jbmr/zjad018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bone and Mineral Research, 2024. Verfasst von Salvatore Minisola und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Internal, Anesthesiologic, and Cardiovascular Sciences, "Sapienza," University of Rome, Rome 00161, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Bone Density Conservation Agents, Osteoporosis, Bone Diseases, Metabolic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vignette A 47-year-old postmenopausal woman with osteoporosis was treated with denosumab, which was discontinued due to side effects. She was therefore transitioned to a yearly intravenous infusion of zoledronic acid. An increase in bone turnover markers together with bone loss at the lumbar spine was observed before the second infusion, suggesting an overshooting of bone resorption due to denosumab discontinuation. On physical examination, the patient was restless and reported having lost about 10 kg since the last visit. A solitary left inferior thyroid nodule was noted on neck palpation. Circulating thyroid hormone levels were elevated, with suppressed thyroid-stimulating hormone. A thyroid scan showed increased uptake in the left inferior nodule with suppression of the remainder of the thyroid gland. A diagnosis of hyperthyroidism due to toxic adenoma was made. The patient was treated with radioactive iodine ablation, with consequent complete normalization of thyroid function. She continued yearly treatment with zoledronic acid. She remained clinically well with no further fractures. Bone turnover markers were appropriately suppressed and bone mineral density increased in the spine and hip. This case illustrates how the overshooting phenomenon following denosumab discontinuation may be compounded by the development of secondary conditions, which can result in suboptimal response to antiresorptive osteoporosis medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsBone Density Conservation AgentsOsteoporosisBone Diseases, MetabolicOsteoporosis, PostmenopausalFemaleHumansMiddle AgedDenosumabZoledronic AcidIodine RadioisotopesBone Density

Stichwörter der Autor:innen

denosumab discontinuationdisorders of calcium/phosphate metabolismsecondary osteoporosistherapeuticstreatment failure

Substanzen

DenosumabZoledronic AcidIodine RadioisotopesBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Clinical, Internal, Anesthesiologic, and Cardiovascular Sciences, "Sapienza," University of Rome, Rome 00161, Italy.

ORCID-Profile: Cristiana Cipriani, Jessica Pepe

Zitieren

APA

Minisola, S., Cipriani, C., Colangelo, L., & Pepe, J. (2024). Bone loss after discontinuation of denosumab: the devil is in the details. Journal of Bone and Mineral Research. https://doi.org/10.1093/jbmr/zjad018

Vancouver

Minisola S, Cipriani C, Colangelo L, Pepe J. Bone loss after discontinuation of denosumab: the devil is in the details. Journal of Bone and Mineral Research. 2024. doi:10.1093/jbmr/zjad018

BibTeX
@article{Minisola2024,
  author = {Minisola, Salvatore and Cipriani, Cristiana and Colangelo, Luciano and Pepe, Jessica},
  title = {Bone loss after discontinuation of denosumab: the devil is in the details},
  journal = {Journal of Bone and Mineral Research},
  year = {2024},
  doi = {10.1093/jbmr/zjad018}
}
Kostenlos starten →